Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Robert F. Kennedy Jr.’s vaccine panel votes to stop recommending flu shots containing thimerosal, which government agencies ...